Mainz Biomed BV (MYNZ NASDAQ) stock market data APIs
$1.8684
0.08(4.3%)
as of July 14, 2025
Try our APIs with
free plan!
Mainz Biomed BV Financial Data Overview
Price chart is built with
Anychart
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Prev. Close
1.8684
Open
1.9486
High
1.9968
Low
1.8072
52 wk Range
1.338-19.004
Market Cap
7 325 K
Shares Outstanding
3 815 K
Revenue
894 K
EPS
-7.71
Beta
0.305
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mainz Biomed BV data using free add-ons & libraries
Get Mainz Biomed BV Fundamental Data
Mainz Biomed BV Fundamental data includes:
- Net Revenue: 894 K
- EBITDA: -17 712 238
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-01
- EPS/Forecast: -6.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mainz Biomed BV News
New
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing...
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing...
Will AI Empower the PR Industry or Create Endless Seas of Spam?
Communications pros are trying everything from generating pitch emails with AI to using facial recognition technology for more accurate survey results. Continue Reading View Comments
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
